ReviewPLoS pathogens2026
Mechanisms of natural and vaccine-induced immunity to Bordetella pertussis.
Review in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- Unadjuvanted antenatal pertussis OMV vaccination drives enhanced and durable humoral immunity in offspring.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bordetella pertussis causes whooping cough (pertussis), a respiratory infectious disease that is resurgent despite high vaccine coverage. Research on the mechanisms of immunity to B. pertussis have demonstrated protective roles for innate immune cells, antibodies and T cells in immunity induced by natural infection. Studies in animal models have demonstrated that IL-17-secreting respiratory tissue-resident memory CD4+ T (TRM) cells and associated recruitment of neutrophils play a critical role in clearance of bacteria from nasal mucosa. However, current acellular pertussis (aP) vaccines, while inducing potent serum antibody responses and protecting against pertussis disease, fail to induce local immune responses in the respiratory tract, thus allowing transmission of the bacteria from vaccinated individuals. Motivated by the resurgence of pertussis and the limitations of the current aP vaccines, several research groups involved in the design of more effective third generation pertussis vaccines are focusing on nasal-delivery approaches that induce respiratory TRM cells and mucosal IgA, as well as circulating antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.